Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Revenue of Pear Therapeutics, Inc. (PEAR)
Revenue in 2022 (TTM): $12.69 M
According to Pear Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $12.69 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pear Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $12.69 M | $4.51 M | $-169,399,000 | $-75,491,000 | $-23,740,000 |
| 2021 | $4.21 M | $-1,025,000 | $-152,425,000 | $-65,142,000 | $-20,294,000 |
| 2020 | $9.38 M | $7.67 M | $-75,215,000 | $-97,023,000 | $-100,583,000 |
| 2019 | $32.56 M | $31.56 M | $-51,704,000 | $-9,334,000 | $12.39 M |